Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13 déc. 2024 08h30 HE
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29 mai 2024 02h00 HE
|
Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
23 mars 2023 03h00 HE
|
Anaveon
BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02 févr. 2023 02h00 HE
|
Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
10 sept. 2022 03h00 HE
|
Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
08 avr. 2022 13h00 HE
|
Anaveon
- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
Anaveon to raise CHF 110 million in oversubscribed Series B financing
16 déc. 2021 02h00 HE
|
Anaveon
- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
04 janv. 2021 08h00 HE
|
Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
08 nov. 2016 09h00 HE
|
XOMA Ltd.
Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone...